Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics (Nasdaq: BCAX) granted inducement equity awards to four new employees under its 2026 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Bicara Therapeutics (Nasdaq: BCAX) granted inducement equity awards to four new employees under its 2026 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).

The grants cover 191,425 stock options at an exercise price of $28.91 per share, with time-based vesting tied to continued service.

Argus Jul 2 session

+0.31% close to close Open Argus

Details

News Market Reaction – BCAX

On Jul 2, the day this news came out, BCAX closed 0.31% above the previous close.

Data tracked by StockTitan Argus for the Jul 2 session.

Key Figures

Inducement option shares: 191,425 shares Exercise price: $28.91 per share Par value: $0.0001 per share +5 more

Inducement option shares

191,425 shares

Aggregate non-qualified stock options granted to four new employees

Exercise price

$28.91 per share

Equals Nasdaq closing price on July 1, 2026

Par value

$0.0001 per share

Par value of Bicara common stock underlying options

Employees receiving grants

4 employees

New hires granted options under 2026 Inducement Plan

Initial vesting portion

One-fourth of shares

Vests on first anniversary of each employee’s start date

Remaining vesting schedule

12 quarterly installments

Balance vests in 12 equal quarterly installments after first anniversary

Grant date

July 1, 2026

Date options were granted under 2026 Inducement Plan

Plan adoption date

January 2026

Bicara’s board adopted the 2026 Inducement Plan

Historical Context

5 past events · Latest: May 21

5 events

1. May 21

   Clinical trial update

   24h Move

   +4.0%

   Phase 1/1b three-year survival data for ficerafusp alfa plus pembrolizumab.

2. May 13

   Inducement option grant

   24h Move

   -6.2%

   Large stock option inducement grant to new Chief Commercial Officer.

3. May 11

   Q1 2026 earnings

   24h Move

   +1.5%

   Q1 2026 results, cash runway into 1H 2029, and pipeline updates.

4. May 04

   Earnings call notice

   24h Move

   +4.8%

   Scheduling announcement for Q1 2026 results and business update call.

5. Mar 30

   FY 2025 earnings

   24h Move

   +3.6%

   Q4/FY 2025 results, Phase 3 initiation, and extended cash runway disclosure.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options, par value, nasdaq listing rule 5635(c)(4), equity incentive plans, +1 more

5 terms

non-qualified stock options financial

"non-qualified stock options to purchase 191,425 shares of Bicara’s common stock"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

par value financial

"common stock, par value $0.0001 per share, with an exercise price"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

nasdaq listing rule 5635(c)(4) regulatory

"as a material inducement to the employees entering into employment with Bicara in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

equity incentive plans financial

"awards were granted outside of Bicara’s stockholder-approved equity incentive plans"

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

inducement plan financial

"four new employees under Bicara’s 2026 Inducement Plan as a material inducement"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on July 1, 2026 to four new employees under Bicara’s 2026 Inducement Plan as a material inducement to employment.

The employees received, in the aggregate, non-qualified stock options to purchase 191,425 shares of Bicara’s common stock, par value $0.0001 per share, with an exercise price of $28.91 per share, equal to the closing price of Bicara’s common stock as reported by Nasdaq on July 1, 2026. One-fourth of the shares vest on the first anniversary of the employee’s applicable start date, with the remaining shares vesting in 12 equal quarterly installments thereafter, subject to the employee’s continued service with the company through each applicable vesting date.

The above-described awards were granted outside of Bicara’s stockholder-approved equity incentive plans and are pursuant to Bicara’s 2026 Inducement Plan, which was adopted by Bicara’s board of directors in January 2026. The awards were approved by the compensation committee of Bicara’s board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with Bicara in accordance with Nasdaq Listing Rule 5635(c)(4).

About Bicara Therapeutics
Bicara is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara has built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This approach was deployed in the development of Bicara’s lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to a human transforming growth factor beta (TGF-β) ligand trap. By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment (TME). Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, which Bicara believes will lead to deep and durable responses and an increase in overall survival, while reducing the potential adverse effects previously associated with systemic TGF-β inhibition. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.

Contacts

Investors:
Rachel Frank
IR@bicara.com

Media:
Tim Palmer
tim.palmer@bicara.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement stock option grants did Bicara Therapeutics (BCAX) announce on July 2, 2026?

Bicara Therapeutics announced non-qualified stock options for 191,425 shares granted to four new employees. According to Bicara, these options were issued under the 2026 Inducement Plan as a material inducement to employment, outside stockholder-approved equity incentive plans.

What is the exercise price of the new Bicara Therapeutics (BCAX) inducement options?

The exercise price of the inducement options is $28.91 per share. According to Bicara, this price equals the closing price of Bicara common stock on Nasdaq on July 1, 2026, the grant date for these awards.

How do the Bicara Therapeutics (BCAX) inducement grants vest for new employees?

The inducement options vest over time based on continued service. According to Bicara, one-fourth of each grant vests on the first anniversary of the employee’s start date, with the remainder vesting in 12 equal quarterly installments thereafter.

Under which plan were the July 2026 Bicara Therapeutics (BCAX) inducement options granted?

The options were granted under Bicara’s 2026 Inducement Plan. According to Bicara, this plan was adopted by the board in January 2026 and is separate from stockholder-approved equity incentive plans, aligning with Nasdaq Listing Rule 5635(c)(4).

Who approved the July 2026 Bicara Therapeutics (BCAX) inducement option awards?

The compensation committee of Bicara’s board of directors approved the awards. According to Bicara, this committee is composed solely of independent directors and approved the grants as a material inducement for the employees to enter employment.

How does Nasdaq Listing Rule 5635(c)(4) relate to Bicara Therapeutics (BCAX) inducement grants?

Nasdaq Listing Rule 5635(c)(4) permits inducement grants outside stockholder-approved plans in specific circumstances. According to Bicara, the July 1, 2026 option awards qualify as material inducements to employment under this rule and were structured accordingly.